Ares Capital Corporation (NASDAQ:ARCC) reported that its Board of Directors has declared a third quarter dividend of 0.38 per share and an additional dividend of 0.05 per share, both payable on September 28, 2012 to stockholders of record as of September 14, 2012. The internet has become one of the most productive sources to bring in consumers of any kind. The internet and especially its continuous growth have attracted for quite a while now the attention of advertising agencies and advertisers in general because of its potential regarding the visibility of the ad. Crown Equity Holdings Inc., (CRWE) offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. CRWEs advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. CRWEs division CRWE AD-Services (www.crwe-adservices.com), is a full service multimedia advertising company specializing in internet marketing. It provides modern and unique advertising campaigns, dedicated to offering the most cost effective advertising solutions. More about CRWE at www.crownequityholdings.com. Hecla Mining Company (NYSE:HL) reported second quarter net income applicable to common shareholders of 2.4 million, or 0.01 per basic share, and earnings after adjustments applicable to common shareholders of 4.4 million, or 0.02 per basic share. Second quarter silver production was 1.4 million ounces at a cash cost of 1.03 per ounce, net of by-products. CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company specializing in oncology, announced that favorable results from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate aldoxorubicin (formerly known as INNO-206) primarily in patients with advanced soft tissue sarcoma will be featured in a poster presentation
at the ESMO (European Society of Medical Oncology) 2012 Congress being held September 28 - October 2 in Vienna, Austria. The abstract INNO-206 is an active drug for relapsed advanced soft tissue sarcoma will be presented by the clinical trials principal investigator and renowned sarcoma expert Sant P. Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology Center in Santa Monica, Calif. The abstract will be published in the ESMO 2012 Congress Abstract Book, which is a supplement to the peer-reviewed ESMO journal Annals of Oncology. THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewsalert.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://crwenewsalert.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold crwenewsalert.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE) advertises for a particular client, Crown Equity Holdings Inc. (CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE), if paid in stock, can and may sell those securities during the advertising period.